MX342326B - 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. - Google Patents
3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.Info
- Publication number
- MX342326B MX342326B MX2014003752A MX2014003752A MX342326B MX 342326 B MX342326 B MX 342326B MX 2014003752 A MX2014003752 A MX 2014003752A MX 2014003752 A MX2014003752 A MX 2014003752A MX 342326 B MX342326 B MX 342326B
- Authority
- MX
- Mexico
- Prior art keywords
- mutant idh
- oxazolidin
- pyrimidin
- inhibitors
- ones
- Prior art date
Links
- DPXAMRSETFKEGX-UHFFFAOYSA-N O=C1OCCN1C1=CC=NC=N1 Chemical class O=C1OCCN1C1=CC=NC=N1 DPXAMRSETFKEGX-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003538 neomorphic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a un compuesto de la fórmula (I): (ver Fórmula) o a una sal farmacéuticamente aceptable del mismo, en donde R1 a R6 se definen en la presente. La invención también se refiere a composiciones que contienen un compuesto de la fórmula (I), y al uso de estos compuestos en la inhibición de las proteínas de IDH mutante que tienen una actividad neomórfica. La invención se refiere además al uso de un compuesto de la fórmula (I) en el tratamiento de las enfermedades o los trastornos asociados con tales proteínas de IDH mutante, incluyendo, pero no limitándose a, los trastornos de proliferación celular, tales como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539553P | 2011-09-27 | 2011-09-27 | |
| PCT/IB2012/055133 WO2013046136A1 (en) | 2011-09-27 | 2012-09-26 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014003752A MX2014003752A (es) | 2014-08-22 |
| MX342326B true MX342326B (es) | 2016-09-26 |
Family
ID=47178237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003752A MX342326B (es) | 2011-09-27 | 2012-09-26 | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8957068B2 (es) |
| EP (1) | EP2771337B1 (es) |
| JP (1) | JP6026544B2 (es) |
| KR (1) | KR20140069235A (es) |
| CN (1) | CN103958506B (es) |
| AP (1) | AP3907A (es) |
| AR (1) | AR088175A1 (es) |
| AU (1) | AU2012313888B2 (es) |
| BR (1) | BR112014007310A2 (es) |
| CA (1) | CA2849995A1 (es) |
| CL (1) | CL2014000746A1 (es) |
| CO (1) | CO6920291A2 (es) |
| CR (1) | CR20140143A (es) |
| CU (1) | CU24269B1 (es) |
| DO (1) | DOP2014000058A (es) |
| EA (1) | EA025183B1 (es) |
| ES (1) | ES2645968T3 (es) |
| GE (1) | GEP20166432B (es) |
| GT (1) | GT201400057A (es) |
| IL (1) | IL231786A (es) |
| MA (1) | MA35452B1 (es) |
| MX (1) | MX342326B (es) |
| NI (1) | NI201400026A (es) |
| PE (1) | PE20141581A1 (es) |
| SG (1) | SG11201400989TA (es) |
| TN (1) | TN2014000128A1 (es) |
| TW (1) | TWI547493B (es) |
| UA (1) | UA111503C2 (es) |
| UY (1) | UY34352A (es) |
| WO (1) | WO2013046136A1 (es) |
| ZA (1) | ZA201402144B (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| EP2822944A1 (en) * | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| SG11201507063YA (en) | 2013-03-14 | 2015-10-29 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| MX2015012822A (es) * | 2013-03-14 | 2016-05-31 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| AU2014287121B2 (en) * | 2013-07-11 | 2018-11-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015010297A1 (en) * | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102456088B1 (ko) | 2014-04-04 | 2022-10-19 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| WO2015193263A1 (en) * | 2014-06-17 | 2015-12-23 | Chiesi Farmaceutici S.P.A. | Indolizine derivatives as phoshoinositide 3-kinases inhibitors |
| AU2015317327B9 (en) | 2014-09-19 | 2020-04-09 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044782A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| WO2016044789A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| EP3194383B1 (en) * | 2014-09-19 | 2019-11-06 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| WO2016048861A2 (en) | 2014-09-22 | 2016-03-31 | National Health Research Institutes | Heterocyclic compounds and use thereof |
| KR102440429B1 (ko) * | 2014-10-01 | 2022-09-05 | 다이이찌 산쿄 가부시키가이샤 | 돌연변이형 이소시트레이트 데히드로게나아제 1 저해제로서의 이속사졸 유도체 |
| JP6672288B2 (ja) * | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール |
| WO2016089833A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| AU2015369712B2 (en) | 2014-12-22 | 2020-05-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Mutant IDH1 inhibitors useful for treating cancer |
| WO2016142886A2 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| PL3267984T4 (pl) | 2015-03-10 | 2022-05-02 | Aurigene Discovery Technologies Limited | Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| TWI681959B (zh) * | 2015-06-09 | 2020-01-11 | 日商第一三共股份有限公司 | 作為變異型異檸檬酸脫氫酶1阻礙劑之異噁唑衍生物 |
| JP6824952B2 (ja) * | 2015-07-07 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール |
| TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶ｉｄｈ１ ｒ１３２ｈ之抑制劑 |
| WO2017019429A1 (en) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| CN107216312B (zh) * | 2016-03-22 | 2023-08-01 | 上海海和药物研究开发股份有限公司 | 一种具有突变型idh抑制活性的化合物、其制备方法及用途 |
| WO2017213910A1 (en) | 2016-06-06 | 2017-12-14 | Eli Lilly And Company | Mutant idh1 inhibitors |
| MA46589A (fr) | 2016-10-24 | 2019-08-28 | Yumanity Therapeutics Inc | Composés et utilisations de ces derniers |
| PE20190977A1 (es) * | 2016-12-16 | 2019-07-09 | Lilly Co Eli | Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes |
| JP2020502116A (ja) * | 2016-12-19 | 2020-01-23 | イソキュア バイオサイエンシーズ インク． | 突然変異イソクエン酸デヒドロゲナーゼの阻害およびその組成物と方法 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| ES2950757T3 (es) | 2017-10-06 | 2023-10-13 | Forma Therapeutics Inc | Inhibición de la peptidasa específica de la ubiquitina 30 |
| BR112020006669A2 (pt) | 2017-10-11 | 2020-09-24 | Aurigene Discovery Technologies Limited | formas cristalinas de 1,2,4-oxadiazol 3-substituído |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| SG11202003625VA (en) | 2017-11-03 | 2020-05-28 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| US11497735B2 (en) | 2017-11-06 | 2022-11-15 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
| CN110407855A (zh) * | 2018-04-26 | 2019-11-05 | 上海嗣新生物科技有限公司 | 2-氨基嘧啶啶衍生物及其制备方法和用途 |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| CN112513036B (zh) | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CN112533903B (zh) * | 2018-06-26 | 2022-08-16 | 昆药集团股份有限公司 | 苯并咪唑衍生物及其作为idh1抑制剂的应用 |
| HRP20230409T1 (hr) | 2018-10-05 | 2023-07-07 | Forma Therapeutics, Inc. | Fuzionirani pirolini koji djeluju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
| WO2020198026A1 (en) * | 2019-03-22 | 2020-10-01 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CN111825666B (zh) | 2019-04-23 | 2024-03-08 | 上海仕谱生物科技有限公司 | 二聚或多聚体形式的突变型idh抑制剂 |
| AU2020311297A1 (en) * | 2019-07-10 | 2022-02-03 | Aucentra Therapeutics Pty Ltd | DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS |
| EP4319766A1 (en) * | 2021-04-08 | 2024-02-14 | Memorial Sloan Kettering Cancer Center | Nadk2 inhibition in cancer and fibrotic disorders |
| WO2023018955A1 (en) | 2021-08-13 | 2023-02-16 | Eli Lilly And Company | Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
| JPS4921148B1 (es) | 1970-12-28 | 1974-05-30 | ||
| JPS4921149A (es) | 1972-06-15 | 1974-02-25 | ||
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| WO1992000970A1 (fr) | 1990-07-03 | 1992-01-23 | Mitsui Petrochemical Industries, Limited | Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose |
| KR100275300B1 (ko) | 1995-04-13 | 2000-12-15 | 고바야시 유키오 | 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof) |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| ES2213286T3 (es) | 1997-07-24 | 2004-08-16 | Zenyaku Kogyo Kabushiki Kaisha | Compuestos heterociclicos y agente antitumoral que los contiene como ingredientes activos. |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| EP0930302B1 (en) | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| ATE274510T1 (de) | 1998-06-19 | 2004-09-15 | Chiron Corp | Glycogen synthase kinase 3 inhibitoren |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| JP2002535318A (ja) | 1999-01-22 | 2002-10-22 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
| DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| JP2003503354A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害剤化合物 |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| CA2379064A1 (en) | 1999-07-15 | 2001-01-25 | Pharmacopeia, Inc. | Bradykinin b1 receptor antagonists |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| KR20030024659A (ko) * | 2000-02-17 | 2003-03-26 | 암겐 인코포레이티드 | 키나제 억제제 |
| HUP0300382A3 (en) | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
| CA2407231A1 (en) | 2000-04-28 | 2002-10-23 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
| EP1296977A1 (en) | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| JP2004514656A (ja) | 2000-09-06 | 2004-05-20 | カイロン コーポレイション | グリコゲンシンターゼキナーゼ３のインヒビター |
| AU2001290914A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| CN102250071A (zh) | 2000-12-21 | 2011-11-23 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1363890A4 (en) | 2001-02-07 | 2009-06-10 | Ore Pharmaceuticals Inc | MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| CA2448626A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003077921A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| ATE365733T1 (de) | 2002-03-15 | 2007-07-15 | Vertex Pharma | Zusammensetzungen brauchbar als protein-kinase- inhibitoren |
| US7179826B2 (en) | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
| US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
| AU2004224392A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| WO2004092196A2 (en) | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| US20060229308A1 (en) | 2003-07-15 | 2006-10-12 | Neurogen Corporation | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands |
| AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| JP2007507529A (ja) * | 2003-09-30 | 2007-03-29 | サイオス・インコーポレーテツド | 複素環式アミドおよびスルホンアミド |
| DE602005024382D1 (de) | 2004-04-13 | 2010-12-09 | Astellas Pharma Inc | Polycyclische pyrimidine als kaliumionenkanal-modulatoren |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| AU2005312048B2 (en) | 2004-11-30 | 2012-08-02 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| AU2005317176A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| WO2006071538A2 (en) | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Substituted biaryl analogues |
| DK1836169T5 (da) | 2004-12-28 | 2023-10-09 | Atnx Spv Llc | Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser |
| CA2595205A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| AU2006217742A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents |
| EP1871762A2 (en) | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CL2007003847A1 (es) * | 2006-12-28 | 2008-04-18 | Basf Ag | Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer. |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| CN101711241A (zh) | 2007-02-06 | 2010-05-19 | 诺瓦提斯公司 | Pi3-激酶抑制剂和它们的使用方法 |
| US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
| EP2074118A2 (en) | 2007-07-09 | 2009-07-01 | AstraZeneca AB | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| EP2259800B1 (en) | 2008-03-05 | 2014-05-07 | Novartis AG | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. |
| RU2509558C2 (ru) | 2008-03-26 | 2014-03-20 | Новартис Аг | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов |
| US20110053907A1 (en) | 2008-03-27 | 2011-03-03 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| US8575338B2 (en) | 2008-04-09 | 2013-11-05 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2349275B1 (en) | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
| PT2394999E (pt) | 2009-02-06 | 2014-05-02 | Nippon Shinyaku Co Ltd | Derivado de aminopirazina e medicamento correspondente |
| MX346801B (es) | 2009-03-13 | 2017-03-31 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular. |
| WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| NZ596123A (en) | 2009-05-19 | 2014-08-29 | Dow Agrosciences Llc | Compounds and methods for controlling fungi |
| TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| US8609676B2 (en) | 2009-08-04 | 2013-12-17 | Merck Sharp & Dohme, Corp. | 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| MX339584B (es) | 2009-09-09 | 2016-06-01 | Avila Therapeutics Inc | Inhibidores de pi3 cinasa y usos de los mismos. |
| EP2509600B1 (en) * | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CA2805669C (en) | 2010-07-16 | 2018-08-21 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| CA2813333C (en) | 2010-10-01 | 2019-01-15 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
| EP3241833A1 (en) | 2010-10-18 | 2017-11-08 | Cerenis Therapeutics Holding SA | Compounds, compositions and methods useful for cholesterol mobilisation |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| CN103476765A (zh) | 2011-02-11 | 2013-12-25 | 达娜-法勃肿瘤研究所公司 | 抑制错构瘤肿瘤细胞的方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| JP2014527542A (ja) | 2011-09-01 | 2014-10-16 | ノバルティス アーゲー | 骨がんの治療に使用するためまたは原発がん細胞の骨への転移性播種を予防するためのｐｉ３ｋ阻害剤 |
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| BR112014028420A2 (pt) | 2012-05-16 | 2017-09-19 | Novartis Ag | regime de dosagem para um inibidor de quinase pi-3 |
| MX2014014969A (es) | 2012-06-06 | 2015-03-13 | Novartis Ag | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. |
| CA2879704A1 (en) | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| WO2014064058A1 (en) | 2012-10-23 | 2014-05-01 | Novartis Ag | Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2012
- 2012-09-26 KR KR1020147010827A patent/KR20140069235A/ko not_active Application Discontinuation
- 2012-09-26 WO PCT/IB2012/055133 patent/WO2013046136A1/en active Application Filing
- 2012-09-26 UA UAA201403086A patent/UA111503C2/uk unknown
- 2012-09-26 BR BR112014007310A patent/BR112014007310A2/pt not_active IP Right Cessation
- 2012-09-26 US US14/347,481 patent/US8957068B2/en active Active
- 2012-09-26 ES ES12784701.0T patent/ES2645968T3/es active Active
- 2012-09-26 CU CUP2014000036A patent/CU24269B1/es unknown
- 2012-09-26 PE PE2014000427A patent/PE20141581A1/es not_active Application Discontinuation
- 2012-09-26 EP EP12784701.0A patent/EP2771337B1/en active Active
- 2012-09-26 CA CA2849995A patent/CA2849995A1/en active Pending
- 2012-09-26 JP JP2014532533A patent/JP6026544B2/ja not_active Expired - Fee Related
- 2012-09-26 SG SG11201400989TA patent/SG11201400989TA/en unknown
- 2012-09-26 MX MX2014003752A patent/MX342326B/es active IP Right Grant
- 2012-09-26 AU AU2012313888A patent/AU2012313888B2/en not_active Ceased
- 2012-09-26 GE GEAP201213450A patent/GEP20166432B/en unknown
- 2012-09-26 TW TW101135421A patent/TWI547493B/zh active
- 2012-09-26 EA EA201490696A patent/EA025183B1/ru not_active IP Right Cessation
- 2012-09-26 AP AP2014007602A patent/AP3907A/en active
- 2012-09-26 CN CN201280058052.3A patent/CN103958506B/zh not_active Expired - Fee Related
- 2012-09-27 AR ARP120103605A patent/AR088175A1/es unknown
- 2012-09-27 UY UY0001034352A patent/UY34352A/es not_active Application Discontinuation
-
2014
- 2014-03-24 ZA ZA2014/02144A patent/ZA201402144B/en unknown
- 2014-03-25 MA MA36849A patent/MA35452B1/fr unknown
- 2014-03-26 NI NI201400026A patent/NI201400026A/es unknown
- 2014-03-26 TN TNP2014000128A patent/TN2014000128A1/en unknown
- 2014-03-26 CL CL2014000746A patent/CL2014000746A1/es unknown
- 2014-03-27 CO CO14065647A patent/CO6920291A2/es active IP Right Grant
- 2014-03-27 IL IL231786A patent/IL231786A/en not_active IP Right Cessation
- 2014-03-27 GT GT201400057A patent/GT201400057A/es unknown
- 2014-03-27 DO DO2014000058A patent/DOP2014000058A/es unknown
- 2014-03-27 CR CR20140143A patent/CR20140143A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| PH12015502018A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| MX2015012822A (es) | 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante. | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| MY162167A (en) | Substituted acetyl-coa carboxylase inhibitors | |
| MX2013004733A (es) | Inhibidores de n1/n2-lactama acetil-coa carboxilasa. | |
| AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
| MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| MX347616B (es) | Inhibidores de csf-1r para el tratamiento de tumores de cerebro. | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| IN2013DN02555A (es) | ||
| EA201270347A1 (ru) | Производные апогоссиполона в качестве противоопухолевых агентов | |
| IN2014KN01113A (es) | ||
| UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
| IN2015MN00045A (es) | ||
| GEP201706680B (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| TN2013000052A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors | |
| TN2013000122A1 (en) | Oxadiazole inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |